-
¹ØÓÚ¹þ¹þÌåÓý
-
-
ÐÂÎŶ¯Ì¬
-
-
Ñз¢ÏîÄ¿
-
Éç»áÔðÈÎ
-
Ͷ×ÊÕß¹Øϵ
²úÆ·ÖÐÐÄ
ÁªÏµ¹þ¹þÌåÓý
ÏúÊÛרÓãº
µØµã£º±±¾©Êк£µíÇøÎ÷С¿Ú·66ºÅÖйش嶫Éý¿Æ¼¼Ô°C-1Â¥Èý²ã
Fmoc Amine PEG Acetic Acid
²úÆ·´úºÅ£º
FMOC-PEG-CM
²úÆ·´¿¶È£º
¡Ý 95%
°ü×°¹æ¸ñ£º
1g, 10g, 100gµÈ£¨ÌØÊâ°ü×°ÐèÊÕÈ¡·Ö×°Óöȣ©
·Ö×ÓÁ¿£º
2000 Da,3500 Da, 5000 Da, 7500 DaµÈ
Òªº¦´Ê£º
ËùÊô·ÖÀࣺ
¿ÆÑпͻ§Ð¡ÅúÁ¿Ò»¼ü²É¹ºµØµã£¨Ð¡ÓÚ5¿Ë£©
- ²úÆ·ÐÎò
- ²Î¿¼ÎÄÏ×
-
¡¡¡¡¹þ¹þÌåÓý¿Æ¼¼Éú²úµÄÒìË«¹¦Ð§Ü̼×ÑõôÊ°±»ù¾ÛÒÒ¶þ´¼ôÈËá²úÆ·Öк¬ÓÐÊܱ £»£»£»¤µÄ°·»ùÍÅ £¬£¬£¬£¬£¬Í¨³£ÓÃ×÷Á½ÖÖ²î±ð»¯Ñ§ÎïÖʵĽ»Áª¼Á»ò¾àÀëÎï¡£¡£¡£´ËÒ칦ЧPEGÑÜÉúÎïÖеÄPEG²¿·Ö¿ÉÌṩˮÈÜÐÔ¡¢ÉúÎïÏàÈÝÐÔ¼°ÈáÐÔ¡£¡£¡£´Ë²úƷרÃÅÓ¦ÓÃÓÚ¿¹ÌåżÁªÒ©Îï(ADC¡¯s)µÄ¿ª·¢¡£¡£¡£
²úÆ·±àÂë
²úÆ·´úºÅ
A5081
FMOC-PEG2000-CM
A5082
MAL-PEG2000-CM
A5083
MAL-PEG5000-CM
A5084
MAL-PEG7500-CM
¡¡¡¡¹þ¹þÌåÓý¿Æ¼¼ÌṩFMOC-PEG-CM·Ö×ÓÁ¿2000 Da,3500 Da, 5000 Da, 7500 DaµÄ²úÆ·1¿ËºÍ10¿Ë°ü×°¡£¡£¡£
¡¡¡¡¹þ¹þÌåÓý¿Æ¼¼Ìṩ·ÖװЧÀÍ £¬£¬£¬£¬£¬ÐèÒªÊÕÈ¡·Ö×°ÓÃ¶È £¬£¬£¬£¬£¬ÈôÊÇÄúÐèÒª·ÖװΪÆäËû¹æ¸ñÇëÓëÎÒÃÇÁªÏµ¡£¡£¡£
¡¡¡¡¹þ¹þÌåÓý¿Æ¼¼Í¬Ê±ÌṩÆäËû·Ö×ÓÁ¿µÄFMOC-PEG-CMÑÜÉúÎï²úÆ· £¬£¬£¬£¬£¬ÈçÄãÐèÒªÇëÓëÎÒ˾sales@jenkem.comÁªÏµ¡£¡£¡£
¡¡¡¡¹þ¹þÌåÓý¿Æ¼¼Ìṩ´óÅúÁ¿Éú²ú²úÆ·¼°GMP¼¶±ð²úÆ· £¬£¬£¬£¬£¬ÈçÐ豨¼ÛÇëÓëÎÒÃÇÁªÏµ¡£¡£¡£
-
¡¡¡¡References:
¡¡¡¡1. Veiman, K.-L., et al., PEG shielded MMP sensitive CPPs for efficient and tumor specific gene delivery in vivo, Journal of Controlled Release, 2015, 209: 238-247.
¡¡¡¡2. Guarnieri, D., et al., Tumor©\activated prodrug (TAP)©\conjugated nanoparticles with cleavable domains for safe doxorubicin delivery, Biotechnology and Bioengineering, 2015, 112(3): 601-611.
¡¡¡¡3. Kuo, C.-H., Inhibition of atherosclerosis-promoting microRNAs via targeted polyelectrolyte complex micelles J. Mater. Chem. B, 2014, 2, 8142-8153.
²úƷѯ¼Û
¹þ¹þÌåÓý
ЧÀÍÈÈÏߣº+86-010-82156767
ÏúÊÛרÓãº+86-010-62983737
²úÆ·×Éѯ£ºsales@jenkem.com
µØµã£º±±¾©Êк£µíÇøÎ÷С¿Ú·66ºÅÖйش嶫Éý¿Æ¼¼Ô°C-1Â¥Èý²ã
΢ÐŹ«ÖÚºÅ
΢ÐŹ«ÖÚºÅ